Showing results (451-460 of 464) with videos related to
Sort By:
Pageof 47
Molecular Cancer Therapeutics|October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4APeggy A Thompson, Boreth Eam, Nathan P Young, et al.BMC Cancer|November 1, 2019
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer CenterMarie K Budde, Walther Kuhn, Mignon-Denise Keyver-Paik, et al.Cell Death & Disease|April 27, 2012
TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell deathJ-Y Chang, M-F Chiang, S-R Lin, et al.Journal of Medicinal Chemistry|July 21, 1998
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studiesP S Dragovich, S E Webber, R E Babine, et al.Journal of Medicinal Chemistry|July 21, 1998
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studiesP S Dragovich, S E Webber, R E Babine, et al.Journal of Cranio-Maxillo-Facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery|June 10, 2015
The current state of facial prosthetics – A multicenter analysisOliver C Thiele, Jörn Brom, Anton Dunsche, et al.Clinical Genetics|August 18, 1999
Chromosome 11q13 and atopic asthmaC N Adra, X Q Mao, H Kawada, et al.Journal of Medicinal Chemistry|March 13, 2018
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) InhibitionSiegfried H Reich, Paul A Sprengeler, Gary G Chiang, et al.Nature Genetics|March 10, 2009
Key susceptibility locus for nonsyndromic cleft lip with or without cleft palate on chromosome 8q24Stefanie Birnbaum, Kerstin U Ludwig, Heiko Reutter, et al.Molecular Cancer Therapeutics|November 26, 2009
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoSean G Buchanan, Jorg Hendle, Patrick S Lee, et al.Pageof 47